Loading clinical trials...

Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis

NCT07029464•The First Affiliated Hospital of Nanchang University

View on ClinicalTrials.gov

Summary

This is a retrospective, multicenter cohort study to compare short- and long-term outcomes between robotic and laparoscopic hemicolectomy of right colon cancer.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1.Underwent radical right hemicolectomy by Da Vinci robotic or laparoscopic surgery 2.Postoperative pathology confirmed right colon adenocarcinoma (pT2-T4aNxM0; including cecal adenocarcinoma, ascending colon adenocarcinoma, hepatic flexure colon adenocarcinoma, and proximal transverse colon adenocarcinoma) 3.Complete clinical data and pathological results available

Exclusion Criteria

•1.Received neoadjuvant therapy prior to surgery 2.History of other malignancies in the past 5 years (except cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin) 3.Distant metastases (e.g., liver, lung) or extensive abdominal/pelvic metastases confirmed by contrast-enhanced CT, PET-CT, or intraoperative exploration 4.Comorbid neurological/psychiatric disorders impairing ability to express informed consent 5.Poor systemic condition with contraindications to general anesthesia 6.Severe obesity (BMI \>35 kg/m²) 7.Severe widespread abdominal adhesions precluding safe pneumoperitoneum establishment 8.Emergency surgery due to tumor perforation or obstruction 9.Refusal to provide informed consent

Key Dates

Start Date

June 1, 2025

Primary Completion Date

May 1, 2026

Completion Date

May 1, 2027

Last Updated

June 19, 2025

Enrollment

4,000

ESTIMATED participants

Conditions

Robotic Surgical ProceduresRight Colon TumorsCancerLaparoscopic Abdominal Surgery

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine Carcinoma+2 more

View study

RECRUITINGEARLY_PHASE1

Pilot Trial of Supplemental Vitamin A and Nicotinamide

NCT05702398

Skin CancerKidney Transplant Recipients

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis

Inclusion Criteria

Exclusion Criteria

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)